34 recruiting, 18 not yet recruiting, 18 unknown, 7 active not recruiting. 60 Phase 2, 12 Phase 3, 9 Phase 1, 3 Not applicable, 2 Phase 4.
Follow disitamab vedotin: new trials by email Literature Review of disitamab vedotin trials Research Report on disitamab vedotin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer Disitamab Vedotin, Toripalimab, Cetirizine - Bladder Cancer | Phase 1 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 20 | 2027-01-01 | 2026-11-05 |
| Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer Disitamab Vedotin and Toripalimab, Toripalimab and Nab-Paclitaxel - Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates | Phase 2 | Not yet recruiting | Tianjin Medical University Second Hospital | 150 | 2026-10-20 | 2026-10-23 |
| Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer Disitamab Vedotin (RC48), Toripalimab, Transurethral Resection of Bladder Tumor - Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer | Phase 2 / Phase 3 | Not yet recruiting | Tianjin Medical University Second Hospital | 114 | 2026-08-01 | 2026-08-10 |
| A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma Sintilimab, disitamab vedotin - Sebaceous Gland Carcinoma | Phase 2 | Not yet recruiting | West China Hospital | 25 | 2026-08-01 | 2026-08-03 |
| Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC Gemcitabine, Toripalimab, Disitamab Vedotin (RC48) - MIBC | Phase 3 | Recruiting | Zhiquan Hu | 170 | 2026-07-01 | 2026-07-09 |
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer Disitamab vedotin, Toripalimab, Sitagliptin - Bladder Urothelial Carcinoma, Bladder Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2026-07-01 | 2026-07-21 |
| HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC Disitamab Vedotin (RC48), Gemcitabine + Cisplatin(GC)+Toripalimab, Toripalimab (JS001 ) - Urinary Bladder Neoplasms | Phase 2 / Phase 3 | Not yet recruiting | West China Hospital | 240 | 2026-06-20 | 2026-05-27 |
| Disitamab Vedotin Combined With Sintilimab and Multimodal Radiotherapy for HER2-Positive Advanced Gastric Cancer After Second-Line Treatment Failure: A Prospective, Single-Arm Phase II Clinical Trial Disitamab vedotin + Sintilimab + Multimodality radiotherapy - HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | West China Hospital | 30 | 2026-06-01 | 2026-08-03 |
| HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC Drug: Disitamab Vedotin - Upper Urinary Tract Urothelial Carcinoma | Phase 2 | Not yet recruiting | RenJi Hospital | 49 | 2026-05-16 | 2026-05-18 |
| Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma Disitamab Vedotin (RC48), radiotherapy, Gemcitabine (1000 mg/m2) - Upper Tract Urothelial Carcinoma | Phase 3 | Recruiting | Peking University First Hospital | 192 | 2026-05-01 | 2026-09-28 |
| Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance disitamab vedotin, sintilimab, capecitabine - Rectal Cancer | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 29 | 2026-04-22 | 2026-04-03 |
| A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer Tunlametinib+PD-1 mAb - Gastric Adenocarcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 76 | 2026-04-01 | 2026-04-02 |
| Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC Probiotic, Disitamab Vedotin, Toripalimab - Muscle Invasive Bladder Cancer (MIBC) | Phase 2 | Not yet recruiting | chenxu | 146 | 2026-03-26 | 2026-03-17 |
| RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure Disitamab Vedotin, Gemcitabine, Capecitabine - HER2-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 / Phase 3 | Not yet recruiting | Fudan University | 268 | 2026-01-16 | 2026-01-26 |
| A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Disitamab Vedotin, Tislelizumab, CAPOX (oxaliplatin/capecitabine) - Gastric Carcinoma | Phase 3 | Recruiting | RemeGen Co., Ltd. | 555 | 2026-01-12 | 2026-09-22 |
| A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection Disitamab Vedotin, PD-1 inhibitor, radiotherapy - Bladder (Urothelial, Transitional Cell) Cancer | Phase 2 | Not yet recruiting | RenJi Hospital | 45 | 2025-09-01 | 2025-08-26 |
| Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer Disitamab Vedotin, Lenvatinib, Pembrolizumab - Biliary Tract Cancer, Disitamab Vedotin | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 65 | 2025-08-30 | 2025-09-08 |
| Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer:a Phase II Study Disitamab Vedotin (RC48), Abiraterone + prednisone - mCRPC | Phase 2 | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 20 | 2025-07-20 | 2025-07-30 |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer Disitamab vedotin - Breast Cancer, Breast Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Pfizer | 74 | 2025-06-30 | 2026-11-05 |
| Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Disitamab Vedotin Injection, Ivonescimab(AK112,a PD-1/VEGF bispecific antibody), Radical Cystectomy with Pelvic Lymph Node Dissection - Bladder Cancer, Muscle-invasive Bladder Cancer | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 30 | 2025-04-30 | 2025-05-04 |
Showing 20 of 78. Sign in to see all of them.
Breast Neoplasms (13) · Stomach Neoplasms (10) · Urinary Bladder Neoplasms (9) · Carcinoma, Transitional Cell (6) · Colorectal Neoplasms (3) · Non-Muscle Invasive Bladder Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma, Sebaceous (1) · Biliary Tract Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1)
RemeGen Co., Ltd. (13) · RenJi Hospital (6) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (6) · Sun Yat-sen University (5) · Seagen, a wholly owned subsidiary of Pfizer (4) · The First Affiliated Hospital with Nanjing Medical University (4) · Tianjin Medical University Second Hospital (4) · West China Hospital (4) · Fudan University (3) · Qilu Hospital of Shandong University (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Peking University First Hospital (2) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2)
China (62) · Australia (5) · Canada (5) · Italy (5) · Spain (5) · United States (5) · Japan (4) · United Kingdom (4) · South Korea (3) · Argentina (2) · Belgium (2) · Brazil (2) · Chile (2) · Germany (2) · Israel (2)
Jianmin Fang, Ph.D (6) · Na Su, PhD (2) · Wenjin Yin, M.D. (2) · Dingwei Ye (1) · Gu Yanhong (1) · Haige Chen (1) · Hailong Hu (1) · Han Liang, Master (1) · Han Liang, Ph.D (1) · Hao Xu, Ph.D (1) · Jieer Ying (1) · Jieer Ying, MD (1) · Jin Li, MD,PhD (1)
PMID 33109737, PMID 40661136, PMID 40774226, PMID 41124210, PMID 41193372, PMID 41816563, PMID 42820775, PMID 42848391
2023 (2), 2025 (1)